📊 IMDX Key Takeaways
Is Insight Molecular Diagnostics Inc. (IMDX) a Good Investment?
Insight Molecular Diagnostics exhibits critical financial distress with negative stockholders equity of -$31.5M, indicating balance sheet insolvency. Operating losses of -$51.1M against $4.1M revenue and free cash flow burn of -$25.4M annually provide only ~5.5 months of cash runway at current burn rates, creating severe liquidity risk. While 56.7% gross margins and 3820% revenue growth suggest product viability, the company lacks a demonstrated path to profitability with operational expenses far exceeding revenues.
Despite a step-change in revenue and a solid gross margin profile, Insight Molecular Diagnostics remains deeply unprofitable with severe operating losses and negative free cash flow. Negative stockholders' equity, weak liquidity, and ongoing cash burn suggest a high probability of further capital raises and dilution until scale and cost discipline materially improve.
Why Buy Insight Molecular Diagnostics Inc. Stock? IMDX Key Strengths
- Strong gross margin of 56.7% indicates viable diagnostic product with pricing power
- Exceptional revenue growth of 3820% YoY demonstrates significant market traction and uptake
- Adequate short-term liquidity with current ratio of 1.27x and quick ratio of 1.23x
- Explosive YoY revenue growth from new traction
- Gross margin of 56.7% supports unit economics
- Low absolute long-term debt ($3.2M)
IMDX Stock Risks: Insight Molecular Diagnostics Inc. Investment Risks
- Negative stockholders equity of -$31.5M indicates technical balance sheet insolvency
- Free cash flow burn of -$25.4M annually against cash position of $11.6M provides only ~5.5 months operational runway
- Massive operating losses of -$51.1M with operating margin of -1260.8% show no path to profitability at current scale
- Negative stockholders’ equity with liabilities exceeding assets
- Severe operating losses and -625.6% FCF margin
- Limited cash runway implying dilution/going-concern risk
Key Metrics to Watch
- Monthly cash burn rate and gross cash position runway
- Quarterly revenue growth sustainability and gross margin maintenance
- Operating expense trajectory and progress toward operating cash flow breakeven
- Operating cash burn and cash runway (cash vs OCF)
- Revenue growth sustainability with gross margin ≥55%
Insight Molecular Diagnostics Inc. (IMDX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Insight Molecular Diagnostics Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
IMDX Profit Margin, ROE & Profitability Analysis
IMDX vs Healthcare Sector: How Insight Molecular Diagnostics Inc. Compares
How Insight Molecular Diagnostics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Insight Molecular Diagnostics Inc. Stock Overvalued? IMDX Valuation Analysis 2026
Based on fundamental analysis, Insight Molecular Diagnostics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Insight Molecular Diagnostics Inc. Balance Sheet: IMDX Debt, Cash & Liquidity
IMDX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Insight Molecular Diagnostics Inc.'s revenue has declined by 48% over the 5-year period, indicating business contraction. The most recent EPS of $-4.66 indicates the company is currently unprofitable.
IMDX Revenue Growth, EPS Growth & YoY Performance
IMDX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $115.0K | -$10.9M | $-0.34 |
| Q2 2025 | $104.0K | -$4.5M | $-0.30 |
| Q1 2025 | $176.0K | -$6.7M | $-0.26 |
| Q3 2024 | $115.0K | -$6.5M | $-0.81 |
| Q2 2024 | $104.0K | -$4.5M | $-0.36 |
| Q1 2024 | $176.0K | $3.0M | $0.40 |
| Q3 2023 | $67.0K | -$6.5M | $-0.81 |
| Q2 2023 | $237.0K | -$5.3M | $-0.83 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Insight Molecular Diagnostics Inc. Dividends, Buybacks & Capital Allocation
IMDX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Insight Molecular Diagnostics Inc. (CIK: 0001642380)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IMDX
What is the AI rating for IMDX?
Insight Molecular Diagnostics Inc. (IMDX) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IMDX's key strengths?
Claude: Strong gross margin of 56.7% indicates viable diagnostic product with pricing power. Exceptional revenue growth of 3820% YoY demonstrates significant market traction and uptake. ChatGPT: Explosive YoY revenue growth from new traction. Gross margin of 56.7% supports unit economics.
What are the risks of investing in IMDX?
Claude: Negative stockholders equity of -$31.5M indicates technical balance sheet insolvency. Free cash flow burn of -$25.4M annually against cash position of $11.6M provides only ~5.5 months operational runway. ChatGPT: Negative stockholders’ equity with liabilities exceeding assets. Severe operating losses and -625.6% FCF margin.
What is IMDX's revenue and growth?
Insight Molecular Diagnostics Inc. reported revenue of $4.1M.
Does IMDX pay dividends?
Insight Molecular Diagnostics Inc. does not currently pay dividends.
Where can I find IMDX SEC filings?
Official SEC filings for Insight Molecular Diagnostics Inc. (CIK: 0001642380) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IMDX's EPS?
Insight Molecular Diagnostics Inc. has a diluted EPS of $-1.65.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IMDX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Insight Molecular Diagnostics Inc. has a STRONG SELL rating with 84% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IMDX stock overvalued or undervalued?
Valuation metrics for IMDX: ROE of N/A (sector avg: 15%), net margin of -1,238.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IMDX stock in 2026?
Our dual AI analysis gives Insight Molecular Diagnostics Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IMDX's free cash flow?
Insight Molecular Diagnostics Inc.'s operating cash flow is $-22.2M, with capital expenditures of $3.2M. FCF margin is -625.6%.
How does IMDX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,238.5% (avg: 12%), ROE N/A (avg: 15%), current ratio 1.27 (avg: 2).